Holen Sie sich die Stockscreener-App
36.77
3.74%
-1.43
Schlusskurs vom Vortag:
$38.20
Offen:
$38.16
24-Stunden-Volumen:
557.99K
Relative Volume:
0.38
Marktkapitalisierung:
$2.91B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.67M
KGV:
-13.47
EPS:
-2.73
Netto-Cashflow:
$-97.30M
1W Leistung:
-6.08%
1M Leistung:
-3.29%
6M Leistung:
+127.12%
1J Leistung:
+175.84%
1-Tages-Spanne:
$36.73
$38.28
1-Wochen-Bereich:
$36.75
$40.60
52-Wochen-Spanne:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER ROAD, RADNOR
Vergleichen Sie MLYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
36.74 | 3.02B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
22NW LP Purchases 98,698 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Pale Fire Capital SE - MarketBeat
Aug Big Picture: How Mineralys Therapeutics Inc stock reacts to inflationary pressuresInsider Buying & Low Volatility Stock Suggestions - BỘ NỘI VỤ
Is Mineralys Therapeutics Inc a good long term investmentMarket Timing Techniques & High Return Investment Plans - earlytimes.in
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - sharewise.com
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Quadrature Capital Ltd - MarketBeat
Is Mineralys Therapeutics Inc. stock a buy for dividend growthJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
How Mineralys Therapeutics Inc. stock valuations compare to rivalsQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - Newser
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys - AOL.com
AZ uses a priority review voucher for baxdrostat filing - pharmaphorum
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Geode Capital Management LLC - MarketBeat
AstraZeneca Moves Ahead of Mineralys With Fast Baxdrostat Review - Citeline News & Insights
Virtus Investment Advisers LLC Sells 7,192 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Prudential Financial Inc. Increases Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga
Will Mineralys Therapeutics Inc. stock rally after Fed decisions - Newser
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing - Sahm
Ensign Peak Advisors Inc Raises Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
(MLYS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital’s Major New Investment - Yahoo Finance
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Franklin Resources Inc. - MarketBeat
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ProShare Advisors LLC Takes $141,000 Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling - Investing.com
Mineralys Therapeutics Insider Sold Shares Worth $43,350,000, According to a Recent SEC Filing - MarketScreener
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m By Investing.com - Investing.com Australia
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Greenland Capital Management LP - MarketBeat
Mineralys Therapeutics, Inc.Common Stock (Nasdaq:MLYS) Stock Quote | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Director’s Major Stock Sale Shakes Up Mineralys Therapeutics! - TipRanks
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m - Investing.com
[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity - Stock Titan
Momentum divergence signals in Mineralys Therapeutics Inc. chartJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
What moving averages say about Mineralys Therapeutics Inc.Trade Exit Report & Community Consensus Picks - newser.com
How rising interest rates impact Mineralys Therapeutics Inc. stock2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Will Mineralys Therapeutics Inc. stock benefit from commodity pricesNew Guidance & Free Safe Entry Trade Signal Reports - newser.com
Mineralys Nears Pivotal FDA Filing as Hypertension Drug Lorundrostat Advances - MSN
Is Mineralys Therapeutics Inc. stock positioned for digital transformationTrade Performance Summary & Safe Swing Trade Setups - newser.com
A Fresh Look at Mineralys Therapeutics (MLYS) Valuation After Narrower Q3 Loss and $300M Shelf Registration - Sahm
How Mineralys Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
Can Mineralys Therapeutics Inc. hit a new high this monthEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Ranking Mineralys Therapeutics Inc. among high performing stocks via toolsEarnings Miss & Weekly Watchlist of Top Performers - newser.com
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):